SIGY Stock Analysis
SI
Uncovered
Sigyn Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Market cap $B
0.007
Dividend yield
—
Shares outstanding
37.296 B
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company, which focuses on the treatment of life-threatening inflammatory conditions that are precipitated by cytokine storm syndrome. The company is headquartered in Beverly Hills, California and currently employs 5 full-time employees. The company went IPO on 2016-01-28. The firm is focused on the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis. The firm designed Sigyn Therapy to extract pathogen sources of life-threating inflammation from the bloodstream in concert with the depletion of pro-inflammatory cytokines, whose dysregulated production (the cytokine storm) plays a role in each of its therapeutic indication opportunities. In addition to sepsis, its candidate treatment indications include emerging pandemic threats, drug-resistant pathogens, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP).